论文信息 - Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy - 字舞流文

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Rajiv Kumar | A. Mahajan | A. Bhattacharjee | K. Prabhash | V. Noronha | V. Patil | A. Joshi | N. Pande | A. Chandrasekharan | A. Ramaswamy | A. Karpe | V. Talreja | N. Purandare | A. Chougule | A. Janu | S. Goud | S. More | A. Goel